Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-512
Closed -$1K 3944
2023
Q2
$1K Buy
512
+452
+753% +$187K ﹤0.01% 3259
2023
Q1
$1K Buy
+60
New +$31.7K ﹤0.01% 3409
2022
Q1
Sell
-232
Closed -$3K 5535
2021
Q4
$3K Sell
232
-44
-16% -$13.7K ﹤0.01% 4498
2021
Q3
$2K Buy
276
+208
+306% +$73.7K ﹤0.01% 4988
2021
Q2
$4K Buy
+68
New +$39.2K ﹤0.01% 4574
2020
Q1
Sell
-36
Closed -$2K 4194
2019
Q4
$2K Sell
36
-60
-63% -$61.3K ﹤0.01% 3431
2019
Q3
$1K Buy
+96
New +$105K ﹤0.01% 3707
2019
Q2
Sell
-76
Closed -$2K 4410
2019
Q1
$2K Buy
+76
New +$103K ﹤0.01% 3370
2018
Q4
Sell
-48
Closed -$13K 4131
2018
Q3
$13K Buy
+48
New +$73.9K ﹤0.01% 2492
2018
Q1
Sell
-56
Closed -$13K 4670
2017
Q4
$13K Sell
56
-44
-44% -$55.2K ﹤0.01% 2916
2017
Q3
$21K Sell
100
-148
-60% -$156K ﹤0.01% 3082
2017
Q2
$19K Sell
248
-1,664
-87% -$1.16M ﹤0.01% 3452
2017
Q1
$51K Buy
1,912
+1,628
+573% +$991K ﹤0.01% 2386
2016
Q4
$13K Sell
284
-1,000
-78% -$499K ﹤0.01% 3900
2016
Q3
$62K Buy
+1,284
New +$605K ﹤0.01% 2241
2016
Q2
Sell
-16
Closed -$1K 6825
2016
Q1
$1K Sell
16
-992
-98% -$494K ﹤0.01% 5960
2015
Q4
$252K Buy
+1,008
New +$669K 0.01% 1003

Other funds holding KYNB

Cutler Group's KYNB Position: Q1 2024 in Review

Cutler Group reduced its Kyntra Bio (KYNB) stake by 74% in Q1 2024, selling an estimated $4.31K and leaving 36 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

Cutler Group first reported a position in KYNB in Q1 2016 and has held it in 28 quarters since. The position peaked at $1.05M in Q3 2017. 112 funds tracked by Wall St. Rank hold KYNB as of Q1 2024.

  • Cutler Group held 36 shares of Kyntra Bio worth $2K as of Q1 2024.
  • Cutler Group sold 100 Kyntra Bio shares in Q1 2024, an estimated $4.31K.
  • Kyntra Bio made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1834 holding.
  • Cutler Group first reported a position in Kyntra Bio in Q1 2016 and has held it in 28 quarters since.
  • Cutler Group's Kyntra Bio position peaked at $1.05M in Q3 2017.
  • 112 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.